App. Serial No. 10/600,361 Response to Office Action dated Feb. 11, 2004

1.- 11. (Canceled)

12. (Currently Amended) The composition of Claim 11 14, wherein said inactivated autologous human immunodeficiency virus is an inactivated autologous human immunodeficiency virus (HIV).

13. (Canceled)

- 14. (Currently Amended) A composition for expanding expression of virus specific CB8+T cells, comprising an autologous dendritic cell antigen presenting cell pulsed with an inactivated human immunodeficiency virus (HIV), wherein the composition expands expression of virus-specific CB8+T cells.
- 15. (Currently Amended) The composition of Claim 14, wherein said virus-specific CBS+T CB8+T cells kill HIV-infected cells.

16.-32. (Canceled)

- 33. (New) The composition of Claim 14, wherein said antigen-presenting cell is a dendritic cell.
- 34. (New) The composition of Claim 33, wherein said dendritic cell is an autologous dendritic cell.
- 35. (New) The composition of Claim 33, wherein the dendritic cell is a monocyte-derived dendritic cell.
- 36. (New) The composition of claim 14, wherein the inactivated human immunodeficiency virus is chemically inactivated.

App. Serial No. 10/600,361 Response to Office Action dated Feb. 11, 2004

37. (New) The composition of claim 14, wherein the inactivated human immunodeficiency virus is inactivated by 2,2'-dithiopyridine or aldrithiol-2.

3